{"id":3920,"date":"2020-09-29T15:49:21","date_gmt":"2020-09-29T14:49:21","guid":{"rendered":"https:\/\/www.ab-science.com\/publications\/"},"modified":"2022-08-24T18:10:04","modified_gmt":"2022-08-24T17:10:04","slug":"publications","status":"publish","type":"page","link":"https:\/\/www.ab-science.com\/fr\/science\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"

[vc_row][vc_column][vc_custom_heading text=\u00a0\u00bbScl\u00e9rose en plaques\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23ffffff\u00a0\u00bb google_fonts=\u00a0\u00bbfont_family:Lato%3A100%2C100italic%2C300%2C300italic%2Cregular%2Citalic%2C700%2C700italic%2C900%2C900italic|font_style:700%20bold%20regular%3A700%3Anormal\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1604307322281{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #00477a !important;}\u00a0\u00bb]

<\/div>[vc_column_text]Efficacy and safety of masitinib in progressive forms of multiple sclerosis: A randomized, phase 3, clinical trial<\/em><\/a> by Vermersch P, et al. in Neurol Neuroimmunol Neuroinflamm (2022).<\/strong><\/p>\n

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study<\/a><\/em> by Vermersch P et al. in BMC Neurol (2013)<\/strong>.[\/vc_column_text][vc_custom_heading text=\u00a0\u00bbScl\u00e9rose Lat\u00e9rale Amyotrophique\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23ffffff\u00a0\u00bb google_fonts=\u00a0\u00bbfont_family:Lato%3A100%2C100italic%2C300%2C300italic%2Cregular%2Citalic%2C700%2C700italic%2C900%2C900italic|font_style:700%20bold%20regular%3A700%3Anormal\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1604307354985{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #00477a !important;}\u00a0\u00bb]

<\/div>[vc_column_text]Long-term survival analysis of masitinib in amyotrophic lateral sclerosis<\/em><\/a> by Mora JS, et al. in Ther Adv Neurol Disord (2021)<\/strong><\/p>\n

The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS<\/em><\/a> by Kovacs M, et al. in Acta Neuropathol Commun (2021).<\/strong> [<\/em>https:\/\/pubmed.ncbi.nlm.nih.gov\/34389060<\/em>]<\/em><\/p>\n

Muscle fiber-type specific terminal Schwann cell pathology leads to sprouting deficits following partial denervation in SOD1G93A mice<\/a><\/em> by Harrison JM et al. Neurobiol Dis (2020)<\/strong>.<\/em><\/p>\n

Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis<\/a><\/em> by Trias E et al. in Glia (2020)<\/strong>.<\/p>\n

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial<\/em><\/a> by Mora JS et al. in Amyotroph Lateral Scler Frontotemporal Degener (2019).<\/em><\/strong><\/p>\n

Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS<\/a><\/em> by Trias E et al. in JCI Insight (2018)<\/strong>.<\/em><\/p>\n

Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS<\/a><\/em> by Trias E et al. in JCI Insight (2018)<\/strong>.<\/em><\/p>\n

ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?<\/a><\/em> by Petrov D et al. in Front Aging Neurosci (2017)<\/strong>.<\/p>\n

Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis<\/a><\/em> by Trias E et al. in J Neuroinflammation<\/strong> (2017).<\/em><\/p>\n

Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient<\/a><\/em> by Salvado M et al. in World J Gastroenterol (2016).<\/strong>[\/vc_column_text][vc_custom_heading text=\u00a0\u00bbMaladie d’Alzheimer\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23ffffff\u00a0\u00bb google_fonts=\u00a0\u00bbfont_family:Lato%3A100%2C100italic%2C300%2C300italic%2Cregular%2Citalic%2C700%2C700italic%2C900%2C900italic|font_style:700%20bold%20regular%3A700%3Anormal\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1604307397080{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #00477a !important;}\u00a0\u00bb]

<\/div>[vc_column_text]Masitinib in mild to moderate Alzheimer\u2019s disease: Results from study AB09004<\/em><\/a> by Bruno Dubois, et al. in Alzheimer\u2019s & Dementia: Journal of the Alzheimer\u2019s Association (2021).<\/strong><\/p>\n

Effects of chronic masitinib treatment in APPswe\/PSEN1dE9 transgenic mice modeling Alzheimer’s disease<\/a><\/em> by Li T et al. in J Alzheimers Dis (2020)<\/strong>.<\/p>\n

Masitinib for the treatment of mild to moderate Alzheimer’s disease<\/a><\/em> by Folch J et al. in Expert Rev Neurother (2015).<\/strong><\/p>\n

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer\u2019s disease: a randomized, placebo-controlled phase 2 trial<\/em><\/a> by Piette F et al. in Alzheimers Res Ther (2011)<\/strong>.<\/em>[\/vc_column_text][vc_custom_heading text=\u00a0\u00bbMastocytose\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23ffffff\u00a0\u00bb google_fonts=\u00a0\u00bbfont_family:Lato%3A100%2C100italic%2C300%2C300italic%2Cregular%2Citalic%2C700%2C700italic%2C900%2C900italic|font_style:700%20bold%20regular%3A700%3Anormal\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1604307438051{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #00477a !important;}\u00a0\u00bb]

<\/div>[vc_column_text]An evaluation of masitinib for treating systemic mastocytosis<\/a><\/em> by Laforgia M et al. in Expert Opin Pharmacother (2019)<\/strong>.<\/p>\n

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study<\/a><\/em> by Lortholary O et al. in Lancet (2017)<\/strong>.<\/p>\n

Mast cell leukemia: Identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor<\/a><\/em> by Georgin-Lavialle S et al. in Eur J Haematol (2012)<\/strong>.<\/em><\/p>\n

Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy<\/a><\/em> by Moura DS et al. in PLoS One (2011)<\/strong>.<\/em><\/p>\n

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study<\/a><\/em> by Paul C et al. in Am J Hematol (2011)<\/strong>.<\/em>[\/vc_column_text][vc_custom_heading text=\u00a0\u00bbAsthme\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23ffffff\u00a0\u00bb google_fonts=\u00a0\u00bbfont_family:Lato%3A100%2C100italic%2C300%2C300italic%2Cregular%2Citalic%2C700%2C700italic%2C900%2C900italic|font_style:700%20bold%20regular%3A700%3Anormal\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1604307458869{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #00477a !important;}\u00a0\u00bb]

<\/div>[vc_column_text]Efficacy and <\/em>safety of masitinib in corticosteroid-dependent severe asthma: A randomized placebo-controlled trial<\/a> by Davidescu L, et al. in J Asthma Allergy (2022)<\/strong>.<\/p>\n

The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma<\/a><\/em> by Lee-Fowler TM et al. in Int Arch Allergy Immunol (2012)<\/strong>.<\/em><\/p>\n

Masitinib, a c-kit\/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics<\/a><\/em> by Humbert M et al. in Allergy (2009)<\/strong>.[\/vc_column_text][vc_custom_heading text=\u00a0\u00bbCancer du Pancr\u00e9as\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23ffffff\u00a0\u00bb google_fonts=\u00a0\u00bbfont_family:Lato%3A100%2C100italic%2C300%2C300italic%2Cregular%2Citalic%2C700%2C700italic%2C900%2C900italic|font_style:700%20bold%20regular%3A700%3Anormal\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1604307497525{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #00477a !important;}\u00a0\u00bb]

<\/div>[vc_column_text]Mast cells positive for c-Kit receptor and tryptase correlate with angiogenesis in cancerous and adjacent normal pancreatic tissue<\/em><\/a> by Ammendola M, et al. in Cells (2021)<\/strong>.<\/p>\n

Masitinib in treatment of pancreatic cancer<\/a> <\/em>by Waheed A et al. in Expert Opin Pharmacother (2018)<\/strong>.<\/em><\/p>\n

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer<\/a><\/em> by Deplanque G et al. in Ann Oncol (2015).<\/strong><\/p>\n

Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer<\/a><\/em> by Mitry E et al. in Cancer Chemother Pharmacol (2010)<\/strong>.<\/p>\n

Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model<\/a><\/em> by Humbert M et al. in PLoS One (2010)<\/strong>.<\/em>[\/vc_column_text][vc_custom_heading text=\u00a0\u00bbCancer de la Prostate\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23ffffff\u00a0\u00bb google_fonts=\u00a0\u00bbfont_family:Lato%3A100%2C100italic%2C300%2C300italic%2Cregular%2Citalic%2C700%2C700italic%2C900%2C900italic|font_style:700%20bold%20regular%3A700%3Anormal\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1661274328951{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #00477a !important;}\u00a0\u00bb]

<\/div>[vc_column_text]Evaluation of the therapeutic potential of masitinib and expression of its specific targets c-Kit, PDGFR-\u03b1, PDGFR-\u03b2, and Lyn in canine prostate cancer cell lines<\/em><\/a> by Klose K, et al. in Vet Comp Oncol (2022).<\/strong>[\/vc_column_text][vc_custom_heading text=\u00a0\u00bbCOVID-19″ font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23ffffff\u00a0\u00bb google_fonts=\u00a0\u00bbfont_family:Lato%3A100%2C100italic%2C300%2C300italic%2Cregular%2Citalic%2C700%2C700italic%2C900%2C900italic|font_style:700%20bold%20regular%3A700%3Anormal\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1604307532050{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #00477a !important;}\u00a0\u00bb]
<\/div>[vc_column_text]Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2<\/em><\/a> by Drayman N, et al. in Science (2021).<\/strong><\/p>\n

In silico characterization of masitinib interaction with SARS-CoV-2 main protease<\/a><\/em> by Mart\u00ednez-Ortega U, et al. in ChemMedChem (2021)<\/strong>.<\/em><\/p>\n

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro<\/em><\/a> by Drayman N et al. in bioRxiv (2020)<\/strong>.[\/vc_column_text][vc_custom_heading text=\u00a0\u00bbAutres\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23ffffff\u00a0\u00bb google_fonts=\u00a0\u00bbfont_family:Lato%3A100%2C100italic%2C300%2C300italic%2Cregular%2Citalic%2C700%2C700italic%2C900%2C900italic|font_style:700%20bold%20regular%3A700%3Anormal\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1604307550982{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #00477a !important;}\u00a0\u00bb]

<\/div>[vc_column_text]Effects of tyrosine kinase inhibitor-masitinib mesylate on canine mammary tumour cell lines<\/em><\/a> by Ustun-Alkan F, et al. in J Vet Res (2021).<\/strong>
\n<\/em><\/p>\n

Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010-2019)<\/em><\/a> by Kuijlaars M, et al. in J Small Anim Pract (2021).<\/strong><\/p>\n

Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats<\/em><\/a> by Leong ZP et al. in Vascul Pharmacol (2020)<\/strong>.<\/p>\n

Piperazining’ the catalytic gatekeepers: unraveling the pan-inhibition of SRC kinases; LYN, FYN and BLK by masitinib<\/em> by Aljoundi<\/a> AK et al. in Future Med Chem (2019)<\/strong>.<\/em><\/p>\n

Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats<\/em><\/a> by Belin-Rauscent A et al. in Psychopharmacology (2018).<\/strong><\/p>\n

The cKit Inhibitor, Masitinib, Prevents Diabetes-Induced Retinal Vascular Leakage<\/em><\/a> by Kim SR et al. in Invest Ophthalmol Vis Sci (2016)<\/strong>.<\/em><\/p>\n

Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report<\/em><\/a> by Prosvicova J et al. in Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2016)<\/strong>.<\/em><\/p>\n

Local release of masitinib alters in vivo implantable continuous glucose sensor performance<\/em><\/a> by Avula M et al. in Biosens Bioelectron (2015)<\/strong>.<\/em><\/p>\n

Neuroprotective effect of masitinib in rats with postischemic stroke<\/em><\/a> by Kocic I et al. in Naunyn Schmiedebergs Arch Pharmacol (2015).<\/strong> [<\/em>https:\/\/pubmed.ncbi.nlm.nih.gov\/25344204<\/em>]<\/em><\/p>\n

Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance<\/em><\/a> by Kathawala RJ et al. in Int J Oncol (2014)<\/strong>.<\/p>\n

Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study<\/em><\/a> by Kathawala RJ et al. in Mol Cancer Ther (2014)<\/strong>.<\/p>\n

Modulation of the foreign body response to implanted sensor models through device-based delivery of the tyrosine kinase inhibitor, masitinib<\/em><\/a> by Avula MN et al. in Biomaterials (2014)<\/strong>.<\/p>\n

Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein<\/em><\/a> by Zandvliet M et al. in J Vet Pharmacol Ther (2013)<\/strong>.<\/em><\/p>\n

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT<\/em><\/a> by Dubreuil P et al. in PLoS One (2009).<\/strong>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_custom_heading text=\u00a0\u00bbScl\u00e9rose en plaques\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23ffffff\u00a0\u00bb google_fonts=\u00a0\u00bbfont_family:Lato%3A100%2C100italic%2C300%2C300italic%2Cregular%2Citalic%2C700%2C700italic%2C900%2C900italic|font_style:700%20bold%20regular%3A700%3Anormal\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1604307322281{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #00477a !important;}\u00a0\u00bb][vc_column_text]Efficacy and safety of masitinib in progressive forms of multiple sclerosis: A randomized, phase 3, clinical trial by Vermersch P, et al. in Neurol Neuroimmunol Neuroinflamm (2022). Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3970,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3920","page","type-page","status-publish","hentry","description-off"],"yoast_head":"\nPublications – AB Science<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/science\/publications\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Publications\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_custom_heading text=\u00a0\u00bbScl\u00e9rose en plaques\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23ffffff\u00a0\u00bb google_fonts=\u00a0\u00bbfont_family:Lato%3A100%2C100italic%2C300%2C300italic%2Cregular%2Citalic%2C700%2C700italic%2C900%2C900italic|font_style:700%20bold%20regular%3A700%3Anormal\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1604307322281{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #00477a !important;}\u00a0\u00bb][vc_column_text]Efficacy and safety of masitinib in progressive forms of multiple sclerosis: A randomized, phase 3, clinical trial by Vermersch P, et al. in Neurol Neuroimmunol Neuroinflamm (2022). Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/science\/publications\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-24T17:10:04+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/science\\\/publications\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/science\\\/publications\\\/\",\"name\":\"Publications – AB Science\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-09-29T14:49:21+00:00\",\"dateModified\":\"2022-08-24T17:10:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/science\\\/publications\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/science\\\/publications\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/science\\\/publications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Science\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/science\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Publications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Publications – AB Science","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/science\/publications\/","og_locale":"fr_FR","og_type":"article","og_title":"Publications","og_description":"[vc_row][vc_column][vc_custom_heading text=\u00a0\u00bbScl\u00e9rose en plaques\u00a0\u00bb font_container=\u00a0\u00bbtag:h3|text_align:left|color:%23ffffff\u00a0\u00bb google_fonts=\u00a0\u00bbfont_family:Lato%3A100%2C100italic%2C300%2C300italic%2Cregular%2Citalic%2C700%2C700italic%2C900%2C900italic|font_style:700%20bold%20regular%3A700%3Anormal\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1604307322281{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #00477a !important;}\u00a0\u00bb][vc_column_text]Efficacy and safety of masitinib in progressive forms of multiple sclerosis: A randomized, phase 3, clinical trial by Vermersch P, et al. in Neurol Neuroimmunol Neuroinflamm (2022). Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study…","og_url":"https:\/\/www.ab-science.com\/fr\/science\/publications\/","og_site_name":"AB Science","article_modified_time":"2022-08-24T17:10:04+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/science\/publications\/","url":"https:\/\/www.ab-science.com\/fr\/science\/publications\/","name":"Publications – AB Science","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2020-09-29T14:49:21+00:00","dateModified":"2022-08-24T17:10:04+00:00","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/science\/publications\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/science\/publications\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/science\/publications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Science","item":"https:\/\/www.ab-science.com\/fr\/science\/"},{"@type":"ListItem","position":3,"name":"Publications"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=3920"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3920\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3970"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=3920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}